---
title: "Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603998.SH.md"
symbol: "603998.SH"
name: "Hunan Fangsheng Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:45:43.895Z"
locales:
  - [en](https://longbridge.com/en/quote/603998.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603998.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603998.SH.md)
---

# Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SH)

## Company Overview

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), and Qiangli Loquat Dew and others.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.fangsheng.com.cn](https://www.fangsheng.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.38)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 54 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.93% |  |
| Net Profit YoY | 12.16% |  |
| P/B Ratio | 2.66 |  |
| Dividend Ratio | 4.75% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4627351989.71 |  |
| Revenue | 1794318627.66 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 18.03% | A |
| Profit Margin | 17.11% | A |
| Gross Margin | 75.33% | A |
| Revenue YoY | 1.93% | C |
| Net Profit YoY | 12.16% | C |
| Total Assets YoY | -3.00% | D |
| Net Assets YoY | 4.32% | C |
| Cash Flow Margin | 144.49% | B |
| OCF YoY | 1.93% | C |
| Turnover | 0.58 | B |
| Gearing Ratio | 39.93% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Fangsheng Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.93%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "12.16%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.66",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.75%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4627351989.71",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1794318627.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "18.03%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "17.11%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "75.33%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.93%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.16%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.32%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "144.49%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.93%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.58",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "39.93%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.80 | 14/215 | 18.27 | 17.31 | 16.13 |
| PB | 2.62 | 125/215 | 3.21 | 3.00 | 2.78 |
| PS (TTM) | 2.53 | 57/215 | 3.13 | 2.93 | 2.69 |
| Dividend Yield | 4.84% | 12/215 | 4.55% | 3.59% | 2.94% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-26T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.33 |
| Highest Target | 16.64 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603998.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603998.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603998.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603998.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**